Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Emma C. Scott"'
Autor:
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K. Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C. Scott, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, David Soong, Tineke Casneuf, Christopher Chiu, Himal Amin, Ming Qi, Piruntha Thiyagarajah, A. Kate Sasser, Jordan M. Schecter, Maria-Victoria Mateos
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or
Externí odkaz:
https://doaj.org/article/a34eb4051074415eaed565a3bdec8188
Autor:
Emma C. Scott, Richard T. Maziarz, Stephen E. Spurgeon, Eva Medvedova, James Gajewski, Shara Reasor-Heard, Byung Park, Anne Kratz, George V. Thomas, Marc Loriaux, Michael Cascio, Jennifer Podolak, Miranda Gordon, Jennifer Botelho, Edward Stadtmauer, Ravi Amaravadi, Dan T. Vogl
Publikováno v:
Haematologica, Vol 102, Iss 7 (2017)
Externí odkaz:
https://doaj.org/article/8c0ae88fc1684cb1a9fdc9b8d8391b58
Autor:
Emma C. Scott, Scott E. Devine
Publikováno v:
Viruses, Vol 9, Iss 6, p 131 (2017)
The human LINE-1 (or L1) element is a non-LTR retrotransposon that is mobilized through an RNA intermediate by an L1-encoded reverse transcriptase and other L1-encoded proteins. L1 elements remain actively mobile today and continue to mutagenize huma
Externí odkaz:
https://doaj.org/article/0bad4c217b1f4c00934a5ec65b902714
Autor:
Hani Hassoun, Susanna J. Jacobus, Paul G. Richardson, Jeffrey A. Zonder, Peter M. Voorhees, Jonathan L. Kaufman, Andrew J. Yee, Emma C. Scott, Pallawi Torka, Edward Libby, Brandi Reeves, Michael L. Wang, Larry D. Anderson, Carter Milner, Cristina J. Gasparetto, Mounzer Agha, Abdullah Khan, David Duane Hurd, David Avigan, Caitlin Costello, Andrzej Jakubowiak, Sagar Lonial, Noopur Raje, Eva Medvedova, Philip L. McCarthy, Robert Z. Orlowski, Omar Nadeem, Jacob P. Laubach, Marcelo C. Pasquini, Sergio A. Giralt, Kelly Masone, Mehmet K. Samur, Aurore Perrot, Philippe Moreau, Herve Avet-Loiseau, Edie A. Weller, Nikhil C. Munshi, Kenneth C. Anderson
Publikováno v:
Blood. 140:4834-4838
Autor:
Madhav V. Dhodapkar, Emma C. Scott, Khalid Mezzi, Jessica A. Fowler, Noopur Raje, Adam D. Cohen
Table S1 shows ongoing vaccine trials with unpublished data for multiple myeloma disease stages with lower tumor burden/immunosuppression. Table S2 shows checkpoint inhibitor-based trials in patients with relapsed and/or refractory multiple myeloma w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3984d71df88abeb186233fe96c9721a7
https://doi.org/10.1158/1078-0432.22477458.v1
https://doi.org/10.1158/1078-0432.22477458.v1
Autor:
Madhav V. Dhodapkar, Emma C. Scott, Khalid Mezzi, Jessica A. Fowler, Noopur Raje, Adam D. Cohen
The progression of multiple myeloma, a hematologic malignancy characterized by unregulated plasma cell growth, is associated with increasing innate and adaptive immune system dysfunction, notably in the T-cell repertoire. Although treatment advances
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14b55db9e7db72e27970841bc5ffd8d9
https://doi.org/10.1158/1078-0432.c.6529665
https://doi.org/10.1158/1078-0432.c.6529665
Autor:
Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy
Supplementary Figure 1. Detailed flow diagram for ascertainment of DS cases.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92fb0954902c2407558ec6d5284e8399
https://doi.org/10.1158/1078-0432.22476204.v1
https://doi.org/10.1158/1078-0432.22476204.v1
Autor:
Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy
Supplementary Figure 2. Relative risk of DS for frequently co-mutated genes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71d8d24c05387f09c3b40e96cbe4a207
https://doi.org/10.1158/1078-0432.22476201
https://doi.org/10.1158/1078-0432.22476201
Autor:
Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy
Purpose:Differentiation syndrome (DS) is a serious adverse reaction of isocitrate dehydrogenase (IDH) inhibitors ivosidenib and enasidenib in patients with (IDH)1- and IDH2-mutated acute myeloid leukemia (AML), respectively.Experimental Design:During
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1510575c2978fec1ff3aeffe590f66ab
https://doi.org/10.1158/1078-0432.c.6529326
https://doi.org/10.1158/1078-0432.c.6529326
Autor:
Richard Pazdur, R. Angelo de Claro, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara, Dickran Kazandjian, Albert Deisseroth, Sarah E. Dorff, Rosane Charlab, Donna Przepiorka, Ashley F. Ward, Emma C. Scott, Flora Mulkey, Kelly J. Norsworthy
Supplementary Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e47caf63fa5983b418d915cdac7a6bb
https://doi.org/10.1158/1078-0432.22476195
https://doi.org/10.1158/1078-0432.22476195